Is Replimune Group (REPL) Undervalued On Its TUDRIQEV Revenue Story?

Replimune Group (REPL) has drawn fresh attention after recent trading left the stock at $13.45. Sharp swings over the past month and past 3 months have put its clinical-stage profile back under the microscope.

Over a longer horizon, Replimune Group has offered a mixed ride for holders, with a strong year to date share price return of 51.12% and a 1 year total shareholder return of 189.25%, set against total shareholder returns over 3 and 5 years that declined 16.51% and 55.81% respectively as sentiment and risk appetite around its clinical pipeline shifted.

See how Replimune Group compares with other fast-moving biotechs by checking a curated set of 35 healthcare AI stocks in similar high-risk, high-reward territory.

Replimune Group’s sharp rebound over the past year against longer term declines leaves a basic question hanging. Are traders reacting to real progress in the business, or just rotating sentiment around a volatile biotech story as valuation comes into focus?

Most Popular Narrative: 44% Undervalued

On the most followed view of Replimune Group, a fair value of $24 against a last close of $13.45 points to a wide gap that hinges on how its oncolytic platform converts into revenue and margins over time.

The TUDRIQEV label allows injection of superficial, deep and visceral lesions with flexible dosing and retreatment beyond the initial eight doses for patients who keep responding, which can support higher utilization per eligible advanced melanoma patient and therefore greater potential revenue per account over time.

Replimune Group’s in house manufacturing facility in Massachusetts is expected to supply commercial TUDRIQEV within about 60 days of approval and support long term global supply, which can give the company more control over cost of goods and may improve gross margin as volumes scale.

See why 0 investors see Replimune Group as 44% undervalued.

Result: Fair Value of $24 (UNDERVALUED)

Still, Replimune Group faces real pressure if the confirmatory melanoma trial disappoints or if securities lawsuits increase costs and distract management from TUDRIQEV execution.

Find out about the key risks to this Replimune Group narrative.

Next Steps

Mixed signals around Replimune Group can tempt you to lean on headlines rather than hard numbers. Consider reviewing the details for yourself by weighing the 2 key rewards and 5 important warning signs.

Looking for more investment ideas beyond Replimune Group?

If Replimune Group has your attention, do not stop there. Broadening your watchlist with focused stock ideas can sharpen your decision making and surface opportunities you did not expect.

• Target higher income potential by scanning companies with resilient payouts using the 7 dividend fortresses.
• Zero in on quality at a discount by reviewing the 28 high quality undervalued stocks that combine strong fundamentals with attractive pricing.
• Get ahead of the crowd by checking the 19 high quality undiscovered gems that still fly under most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com